Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check4 days agoChange DetectedRemoved the sponsor link 'Click here to find results for studies related to Bayer Healthcare products' from the Bayer Helpful Links section. This change does not affect the core study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.0%

- Check11 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2 with no changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedMinor site version update from v3.4.0 to v3.4.1 with no visible changes to the study details page, eligibility criteria, or results; to avoid alerts from small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision indicator updated from v3.3.3 to v3.3.4; this change does not affect study content or user experience. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedExpanded Locations section with numerous new sites across the US, Argentina, Australia, and many other countries.SummaryDifference3%

- Check91 days agoChange DetectedAdded clarifying sentences about how publications are provided and automatically filled from PubMed, and updated the Revision to v3.3.2. The deletions remove older wording describing the PubMed-derived list and the previous revision number.SummaryDifference0.1%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.